FDA Withdraws Approval of Four Generic Drug Applications
March 14, 2025
March 14, 2025
WASHINGTON, March 14 (TNSFR) -- The Food and Drug Administration (FDA) has announced the withdrawal of approval for four abbreviated new drug applications (ANDAs) following requests from the respective pharmaceutical companies.
These drug products, which are no longer being marketed, include treatments for inflammatory conditions, cancer, and epilepsy. The companies have waived their right to a hearing, and the withdrawal is set to take effect on April 14, 2025.
Among . . .
These drug products, which are no longer being marketed, include treatments for inflammatory conditions, cancer, and epilepsy. The companies have waived their right to a hearing, and the withdrawal is set to take effect on April 14, 2025.
Among . . .